$LUNG Cashflow Statement | Understand Stock

$LUNG

$1.98 +$0.03 (1.54%) Close

$LUNG Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense
Change in fair value of derivative liability
Write-off of fixed assets
Gain on disposal of fixed assets
Impairment of capitalized software development costs
Change in allowance for credit losses
Inventory write-down (recovery), net
Depreciation and amortization expense
Amortization of debt discount and debt issuance costs
Write-off of deferred offering costs
Net accretion of discounts on marketable securities
Non-cash lease expense
Net changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Income taxes payable
Lease liabilities
Deferred tax liability
Deferred revenue

Net cash used in operating activities
Cash flows from investing activities
Purchases of investments
Maturities of investments
Purchases of property and equipment
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from borrowing under term loans, net of payment of lender fees and costs
Repayment of term loans
Payment of Success Fee
Proceeds from the issuance of convertible note, net of payment of lender fees and costs (includes $0 and $0 from related party for the years ended December 31, 2021 and 2020, respectively)
Proceeds from Paycheck Protection Program loan
Repayment of Paycheck Protection Program loan
Proceeds from borrowing under term loan
Repayment of credit agreement
Debt issuance cost
Payments of deferred offering costs
Proceeds from exercise of warrants for Series C-1 convertible preferred stock
Proceeds from exercise of common stock options
Proceeds from issuance of common stock under the employee stock purchase plan
Proceeds from initial public offering, net of offering costs
Payments for the repurchase of early exercised common stock options
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents, and restricted cash
Net decrease in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents, and restricted cash at end of year
Supplemental non-cash items:
Lapse in repurchase rights of common stock
Purchases of property and equipment in accounts payable and accrued liabilities
Issuance of derivative instrument related to convertible notes
Operating lease right of use assets obtained in exchange for new lease liabilities
Amount receivable from exercise of Options
Amount receivable from exercise of common stock options

Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Reconciliation of cash, cash equivalents, and restricted cash to consolidated balance sheets:
Cash and cash equivalents
Restricted cash

Comments